"Depsipeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds consisting of chains of AMINO ACIDS alternating with CARBOXYLIC ACIDS via ester and amide linkages. They are commonly cyclized.
| Descriptor ID |
D047630
|
| MeSH Number(s) |
D04.345.566.297 D12.644.641.297
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Depsipeptides".
Below are MeSH descriptors whose meaning is more specific than "Depsipeptides".
This graph shows the total number of publications written about "Depsipeptides" by people in this website by year, and whether "Depsipeptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 2 | 3 |
| 2006 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2010 | 3 | 1 | 4 |
| 2011 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Depsipeptides" by people in Profiles.
-
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2025 May; 25(5):328-336.
-
Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome. Br J Haematol. 2019 07; 186(2):377-379.
-
Multidrug-Resistant Enterococcal Infections: New Compounds, Novel Antimicrobial Therapies? Trends Microbiol. 2017 06; 25(6):467-479.
-
Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma. JAMA Oncol. 2016 Jun 01; 2(6):790-3.
-
Use of class I histone deacetylase inhibitor romidepsin in combination regimens. Leuk Lymphoma. 2016 08; 57(8):1755-65.
-
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug; 33(4):901-10.
-
Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45.
-
Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies. Expert Opin Pharmacother. 2010 Dec; 11(18):3073-84.
-
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol. 2010 Oct; 5(10):1644-8.
-
MEK modulates force-fluctuation-induced relengthening of canine tracheal smooth muscle. Eur Respir J. 2010 Sep; 36(3):630-7.